We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 93.03%
This Fund
S&P 500
This Quarter Est. Return
+16.12%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$3.94B
AUM Growth
+$295M
Cap. Flow
+$29.2M
Cap. Flow %
0.74%
Top 10 Hldgs %
26.69%
Holding
163
New
20
Increased
50
Reduced
30
Closed
15

Top Buys

Rank Stock Value
1
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$44.7M
2
ACAD icon
Acadia Pharmaceuticals
ACAD
+$22.4M
3
INZY
Inozyme Pharma
INZY
+$21.9M
4
KYMR icon
Kymera Therapeutics
KYMR
+$21.7M
5
HUM icon
Humana
HUM
+$20.7M

Top Sells

Rank Stock Value
1
PTLA
Portola Pharmaceuticals, Inc.
PTLA
+$41.5M
2
VRTX icon
Vertex Pharmaceuticals
VRTX
+$32M
3
CI icon
Cigna
CI
+$30.2M
4
AMGN icon
Amgen
AMGN
+$29.7M
5
ALLO icon
Allogene Therapeutics
ALLO
+$18.9M

Sector Composition

Rank Sector Weight
1 Healthcare 90.05%
2 Consumer Staples 1.43%
3 Consumer Discretionary 0.93%
4 Industrials 0.32%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BIIB icon
26
Biogen
BIIB
$30.6B
$48.9M 1.24%
172,500
-7,500
-4% -$2.09M
SGEN
27
DELISTED
Seagen Inc. Common Stock
SGEN
$48.9M 1.24%
250,000
– –
SRPT icon
28
Sarepta Therapeutics
SRPT
$1.81B
$48.5M 1.23%
345,500
– –
RARE icon
29
Ultragenyx Pharmaceutical
RARE
$2.64B
$47.4M 1.2%
576,841
-70,000
-11% -$5.8M
ALGN icon
30
Align Technology
ALGN
$12.5B
$46.8M 1.19%
143,000
– –
EW icon
31
Edwards Lifesciences
EW
$53B
$46.5M 1.18%
582,000
– –
EHC icon
32
Encompass Health
EHC
$12.5B
$45.4M 1.15%
877,386
-169,067
-16% -$8.68M
TFX icon
33
Teleflex
TFX
$5.89B
$44.3M 1.12%
130,000
– –
EXAS
34
DELISTED
Exact Sciences
EXAS
$43.2M 1.1%
424,000
– –
BSX icon
35
Boston Scientific
BSX
$73.1B
$42M 1.07%
1,100,000
– –
ASND icon
36
Ascendis Pharma A/S
ASND
$16.8B
$36M 0.91%
233,500
+20,000
+9% +$2.87M
MRSN
37
DELISTED
Mersana Therapeutics
MRSN
$35.1M 0.89%
75,417
+280
+0.4% +$141K
PEN icon
38
Penumbra
PEN
$12.8B
$30.9M 0.78%
159,000
-48,000
-23% -$10.1M
ADPT icon
39
Adaptive Biotechnologies
ADPT
$4.05B
$30.9M 0.78%
635,000
+60,000
+10% +$2.52M
CHRS icon
40
Coherus Oncology
CHRS
$192M
$30.5M 0.78%
1,665,449
-359,826
-18% -$6.69M
INSP icon
41
Inspire Medical Systems
INSP
$1.73B
$30.5M 0.77%
236,000
-29,000
-11% -$3.2M
EPZM
42
DELISTED
Epizyme, Inc
EPZM
$30.4M 0.77%
2,551,659
+447,575
+21% +$5.99M
MDGL icon
43
Madrigal Pharmaceuticals
MDGL
$11.9B
$30.2M 0.77%
254,268
– –
CVET
44
DELISTED
Covetrus, Inc. Common Stock
CVET
$29.9M 0.76%
1,225,000
+387,500
+46% +$8.36M
INCY icon
45
Incyte
INCY
$24.6B
$26.9M 0.68%
300,000
+50,000
+20% +$4.82M
ARDX icon
46
Ardelyx
ARDX
$997M
$26.7M 0.68%
5,076,867
+61,758
+1% +$371K
BMRN icon
47
BioMarin Pharmaceuticals
BMRN
$13.3B
$26.6M 0.68%
350,000
-37,500
-10% -$3.79M
IMVT icon
48
Immunovant
IMVT
$8.24B
$26.1M 0.66%
742,449
+290,130
+64% +$8.73M
ALXN
49
DELISTED
Alexion Pharmaceuticals
ALXN
$25.7M 0.65%
225,000
+41,500
+23% +$4.48M
HCAT icon
50
Health Catalyst
HCAT
$127M
$25.7M 0.65%
703,000
+278,000
+65% +$9.44M
1
2
3 4 5

Similar funds

ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return
JIP
Jaffetilchin Investment Partners Tampa, Florida $1.68B AUM 22.81% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return

Rock Springs Capital Management's Q3 2020 Portfolio in Review

As of Q3 2020, Rock Springs Capital Management held 163 positions worth $3.94B, up 8.1% from $3.65B the previous quarter. Its ten largest holdings account for 27% of the portfolio.

Rock Springs Capital Management's Q3 2020 filing shows 20 new, 50 increased, 30 reduced and 15 closed positions. Its largest new stake was Horizon Therapeutics Public Limited Company Ordinary Shares: 650,000 shares worth $50.5M. The largest sale was Portola Pharmaceuticals, Inc., an estimated $41.5M.

By sector, the portfolio is most concentrated in Healthcare at 90% of assets, down from 92% a quarter earlier, followed by Consumer Staples and Consumer Discretionary.

  • Rock Springs Capital Management's largest Q3 2020 buy was Horizon Therapeutics Public Limited Company Ordinary Shares: 650,000 shares worth $50.5M.
  • Rock Springs Capital Management added most to Acadia Pharmaceuticals in Q3 2020, an estimated $22.4M increase.
  • Rock Springs Capital Management's biggest Q3 2020 reduction was Vertex Pharmaceuticals, cutting an estimated $32M.
  • Rock Springs Capital Management fully exited Portola Pharmaceuticals, Inc. in Q3 2020, selling an estimated $41.5M.
  • Rock Springs Capital Management's ten largest holdings make up 27% of its $3.94B portfolio in Q3 2020.
  • Rock Springs Capital Management opened 20 new positions and closed 15 in Q3 2020.
  • Rock Springs Capital Management's portfolio value rose 8.1% quarter-over-quarter to $3.94B.

Based on Rock Springs Capital Management's 13F filing for Q3 2020, filed 16 Nov 2020.